This finding directly points to the treatment strategy, for example, the addition of BCR::ABL1 tyrosine kinase inhibitors (TKIs) to intensive chemotherapy has significantly improved outcomes for patients with Philadelphia chromosome-positive (Ph+) ALL. Here, ABL1 is linked to acute lymphoblastic leukemia.